Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Alcon reported revenue of $2.43 billion for Q3 2024, reflecting a 5.6% increase year-over-year, with EPS at$ 0.81 compared to $0.66 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate by 0.78%, while the EPS exceeded the consensus estimate by 12.5% [1] Financial Performance Metrics - Net sales in the United States reached$ 1.11 billion, slightly above the estimated $1.10 billion [3] - International net sales totaled$ 1.32 billion, below the estimated $1.34 billion, marking a year-over-year increase of 6.5% [3] - Total Surgical net sales were$ 1.34 billion, matching the average estimate, with a year-over-year growth of 4.9% [3] - Total Vision Care net sales amounted to $1.10 billion, aligning with estimates and showing a 6.6% increase from the previous year [3] - Total Surgical Consumables generated$ 701 million, slightly above the estimate of $700.88 million, reflecting a 6.1% year-over-year increase [3] - Total Surgical Equipment/Other sales were$ 215 million, slightly below the estimate of $216.17 million, with a 0.5% year-over-year increase [3] - Total Vision Care Contact Lenses sales reached$ 664 million, matching estimates and showing an 8.5% year-over-year increase [3] - Total Vision Care Ocular Health sales were $431 million, below the estimate of$ 438.87 million, with a 3.9% year-over-year increase [3] - Total Surgical Implantables sales were $422 million, slightly below the estimate of$ 426.85 million, reflecting a 5.2% year-over-year increase [3] - Other revenues were reported at $21 million, exceeding the estimate of$ 20.25 million [3] Stock Performance - Alcon's shares have declined by 5.1% over the past month, contrasting with the S&P 500 composite's increase of 3.3% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]